Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
P/E ratio for Esperion Therapeutics, Inc. (ESPR)
P/E ratio as of 2023: -1.47
According to Esperion Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.47. At the end of 2022 the company had a P/E ratio of -1.44.
P/E ratio history for Esperion Therapeutics, Inc. from 1999 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.47 |
| 2022 | -1.44 |
| 2021 | -0.45 |
| 2020 | -4.30 |
| 2019 | -14.82 |
| 2018 | -6.10 |
| 2017 | -9.44 |
| 2016 | -3.76 |
| 2015 | -9.85 |
| 2014 | -18.20 |
| 2013 | -4.15 |
| 2012 | -0.89 |
| 2011 | -0.97 |
| 2002 | -2.11 |
| 2001 | -2.27 |
| 2000 | -1.55 |
| 1999 | -1.83 |